DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 16, 2024, by DarioHealth Corp. (DRIO), a Delaware corporation. The filing details a private placement financing transaction and an amendment to an existing loan agreement. The initial closing of the preferred stock offering occurred on December 18, 2024.
Key Financial Metrics and Capital Structure
- Financing Proceeds: The Company raised approximately $18,805,000 in gross proceeds from the sale of Series D and Series D-1 Preferred Stock.
- Stock Issuance: 7,055 shares of Series D Preferred Stock and 11,750 shares of Series D-1 Preferred Stock were sold at $1,000 per share.
- Conversion Terms: Initial conversion price is $0.73 per share. Holders are entitled to dividends equal to 10% of the underlying common shares for four quarters.
- Liquidity Position: Pro forma cash balance is approximately $34 million as of the end of the third quarter, inclusive of the new offering proceeds.
- Debt Modification: The maturity date of the Avenue loan was extended from May 1, 2027, to November 1, 2027, subject to meeting specific milestones.
Material Changes and Agreements
The filing reports two primary material changes:
- Private Placement: Entry into securities purchase agreements for the Series D and D-1 Preferred Stock. The Series D stock carries voting rights on an as-converted basis, while Series D-1 does not. Both convert automatically after 12 months, subject to a 19.99% beneficial ownership blocker.
- Debt Restructuring: Execution of the Second Amendment to the Loan and Security Agreement with Avenue Venture Opportunities Fund. This amendment extends the interest-only period (potentially up to 36 months total) contingent on equity financing and revenue milestones. It also includes provisions to reprice lender warrants to the Nasdaq "minimum price" ($0.7208) and allows lenders to convert up to $2 million of principal at $0.8650 per share.
Outlook, Management Commentary, and Risks
Management states that cost optimization following the acquisition of Twill Inc. and consistent revenue growth have positioned the Company on a path to profitability. The proceeds from the offering are expected to support achieving a profitability run rate by the end of 2025. Combined with the debt refinancing, the Company expects its cash runway to extend until operational profitability is achieved.
Risks and Contingencies: The debt extension is conditional on the Company achieving specific net revenue milestones and maintaining cash burn below a certain threshold. The conversion of preferred stock is subject to stockholder approval. The filing includes standard forward-looking statement disclaimers regarding potential deviations from projected results.
Investor Verification Checklist
- Verify the exact terms of the "multi-million dollar" revenue and cash burn milestones required to extend the Avenue loan interest-only period.
- Confirm the status of stockholder approval required for the conversion of Preferred Stock and the repricing of Avenue lender warrants.
- Review the full text of the Lock-Up Agreement regarding the 40% issuance cap on Series B and C underlying shares over 12 months.
- Assess the dilution impact of the 10% quarterly dividend shares issuable upon conversion of the new Preferred Stock.
- Monitor the Company's progress toward the stated goal of a profitability run rate by the end of 2025.